Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 652 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dry Eye Syndrome Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dailies Total 1 Sphere Contact Lenses

NCT05239494
View directory record Official record
Conditions
Dry Eye, Contact Lens Complication
Interventions
DT1 Sphere Contact Lenses
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
4
States / cities
Birmingham, Alabama • Pittsburg, Kansas • Granville, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 21, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of a Multidose Preservative-free Lubricating Eye Drops Contained in Novelia® Eye Dropper in Non-Contact Lens Wearing Patients

NCT05661851
View directory record Official record
Conditions
Dry Eye
Interventions
Investigational Lubricating Eye Drop in a Novelia® bottle, Blink® Tears eye Drops
Drug
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
8
States / cities
Jacksonville, Florida • Pittsburg, Kansas • Medina, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 21, 2026, 1:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality

NCT00622037
View directory record Official record
Conditions
Dry Eye
Interventions
PEG-400 based artificial tear, Systane
Drug
Lead sponsor
Bp Consulting, Inc
Network
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2010 · Synced Oct 21, 2026, 1:53 AM EDT
Completed Phase 4 Interventional

Treatment Regimens in Meibomian Gland Dysfunction

NCT05594745
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Lifitegrast Ophthalmic, Systane Free, Lipiflow
Drug · Device
Lead sponsor
Tauber Eye Center
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 21, 2026, 1:53 AM EDT
Withdrawn Phase 4 Interventional

Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease in Contact Lens Wearers

NCT03431272
View directory record Official record
Conditions
Contact Lens Dry Eye
Interventions
Lifitegrast
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 21, 2026, 1:53 AM EDT
Completed Phase 2 Interventional

NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye

NCT00739349
View directory record Official record
Conditions
Dry Eye
Interventions
NOVA22007 ''Cyclosporine'', vehicle/placebo
Drug
Lead sponsor
Santen SAS
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Lewiston, Maine
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Oct 21, 2026, 1:53 AM EDT
Completed Phase 3 Interventional Results available

A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease

NCT01212471
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Bromfenac Ophthalmic Solution A, Bromfenac Ophthalmic Solution B, Placebo Comparator
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 21, 2026, 1:53 AM EDT
Completed Phase 2Phase 3 Interventional Results available

CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

NCT03292809
View directory record Official record
Conditions
Dry Eye Disease
Interventions
CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Newport Beach, California • Torrance, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 21, 2026, 1:53 AM EDT
Withdrawn Phase 2 Interventional

Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study

NCT02027298
View directory record Official record
Conditions
Primary Sjogren's Syndrome, Secondary Sjogren's Syndrome, Inflammatory Arthritis, Rheumatoid Arthritis
Interventions
Abatacept
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 21, 2026, 1:53 AM EDT
Completed Phase 1 Interventional

A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)

NCT02614716
View directory record Official record
Conditions
Sjögren's Syndrome
Interventions
LY3090106, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Baltimore, Maryland • Albuquerque, New Mexico • Concord, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 21, 2026, 1:53 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Effect of Rinsing on Ocular Inflammation and Symptoms in Patients With Dry Eye Disease

NCT07618364
View directory record Official record
Conditions
Dry Eye Syndromes, Dry Eye, Ocular Surface Disease
Interventions
Rinsada
Device
Lead sponsor
Rinsada
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 21, 2026, 1:53 AM EDT
Completed No phase listed Observational

Evaluation of the Role of the Autonomic Nervous System in Sj(SqrRoot)(Delta)Gren s Syndrome

NCT00565526
View directory record Official record
Conditions
Sjogren's Syndrome, Dysautonomia
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 21, 2026, 1:53 AM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of Raptiva to Treat Sjogren's Syndrome

NCT00344448
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Raptiva
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 21, 2026, 1:53 AM EDT
Completed Not applicable Interventional Results available

Safety and Tolerability of Artificial Tears in Dry Eye Subjects

NCT00932477
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear, Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear, Glycerin and Polysorbate 80 based artificial tear
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 21, 2026, 1:53 AM EDT
Completed Phase 3 Interventional

A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease

NCT03527212
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
SJP-0035 0.001%, Placebo
Drug
Lead sponsor
Senju Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
23
States / cities
Chandler, Arizona • Sun City, Arizona • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 21, 2026, 1:53 AM EDT
Completed No phase listed Observational

An Observational Study to Assess Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)

NCT06443775
View directory record Official record
Conditions
Dry Eye
Interventions
Next Generation Emulsion Preservative Free Eye Drops (NGE-UD)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Town and Country, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 21, 2026, 1:53 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Objective Evaluation of Ocular Surface Lubricants in Two Environments

NCT01375582
View directory record Official record
Conditions
Dry Eye
Interventions
B & L Soothe Lubricant Eye Drops, Liposic EDO, OcuFresh Eye Wash
Drug
Lead sponsor
University of Rochester
Other
Eligibility
30 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 21, 2026, 1:53 AM EDT
Completed Phase 1Phase 2 Interventional

Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

NCT01118754
View directory record Official record
Conditions
Dry Eye
Interventions
DE-101 ophthalmic suspension, DE-101 ophthalmic suspension vehicle
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
10
States / cities
Inglewood, California • Torrance, California • Bloomfield, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2011 · Synced Oct 21, 2026, 1:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ocular Surface Immune Response in Dry Eye Disease

NCT02042820
View directory record Official record
Conditions
Dry Eye Disease
Interventions
In vivo confocal microscopy (IVCM)
Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Oct 21, 2026, 1:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Effectiveness Assessments of Restylane-Defyne for Punctual Occlusion

NCT04022382
View directory record Official record
Conditions
Dry Eye
Interventions
Restylane Defyne
Device
Lead sponsor
John C Meyer, MD
Other
Eligibility
21 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 21, 2026, 1:53 AM EDT
Terminated Phase 4 Interventional Results available

The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye

NCT00553735
View directory record Official record
Conditions
Dry Eye
Interventions
Cyclosporine A 0.05%, Arificial Tear
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 21, 2026, 1:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease

NCT04139122
View directory record Official record
Conditions
Dry Eye Disease, Dry Eye Syndrome
Interventions
SJP-0132, Placebo
Drug
Lead sponsor
Senju Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 21, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Results available

Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome

NCT02291029
View directory record Official record
Conditions
Primary Sjögren's Syndrome
Interventions
CFZ533 active - Cohort 1, CFZ533 placebo- Cohort 1, CFZ533 active - Cohort 2, CFZ533 placebo - Cohort 2, CFZ533 active - Cohort 3
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • Mineola, New York • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 21, 2026, 1:53 AM EDT
Completed Not applicable Interventional Results available

Pilot Study of TearCare System - Long-Term Extension

NCT03804502
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
TearCare
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Arlington Heights, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 21, 2026, 1:53 AM EDT